and monitoring of recurrence and metastases as well as alternative targeted therapy with minimal side effects for breast cancer patients remains warranted. The Na + /I − symporter (NIS (SLC5A5)) is a transmembrane glycoprotein that mediates active
Search Results
Zhaoxia Zhang, Sasha Beyer, and Sissy M Jhiang
Aparna Lakshmanan, Anna Wojcicka, Marta Kotlarek, Xiaoli Zhang, Krystian Jazdzewski, and Sissy M Jhiang
Introduction Na + /I − symporter (NIS)-mediated radioiodide uptake (RAIU) in thyroid cells allows for targeted treatment of thyroid cancer. Many patients with advanced thyroid cancer do not benefit from radioiodine therapy due to reduced
Zongjing Zhang, Dingxie Liu, Avaniyapuram Kannan Murugan, Zhimin Liu, and Mingzhao Xing
with decreased or lost expression of thyroid iodide-handling genes in PTC, particularly sodium iodide symporter (NIS; Xing 2007 a , Kim et al . 2012 , Xing et al . 2013 a ), which is normally localized in the basal membrane of thyroid cells and
Christina Schug, Sarah Urnauer, Carsten Jaeckel, Kathrin A Schmohl, Mariella Tutter, Katja Steiger, Nathalie Schwenk, Markus Schwaiger, Ernst Wagner, Peter J Nelson, and Christine Spitzweg
MSCs as a tool to deliver therapeutic genes, such as the sodium iodide symporter ( NIS ), deep into tumor microenvironments ( Hagenhoff et al. 2016 , Melzer et al. 2016 ). NIS is an intrinsic transmembrane glycoprotein with 13 putative
Camille Buffet, Johanna Wassermann, Fabio Hecht, Laurence Leenhardt, Corinne Dupuy, Lionel Groussin, and Charlotte Lussey-Lepoutre
membrane of normal and tumoral thyroid epithelial cells of a symporter, the sodium iodide symporter (NIS), that transports two sodium ions and one iodide ion into the cytosol. Iodide is then handled by an iodine-metabolizing machinery that concentrates
Garcilaso Riesco-Eizaguirre, Pilar Santisteban, and Antonio De la Vieja
characterized ( Dai et al. 1996 ). Nancy Carrasco’s group demonstrated that a sodium/iodide symporter (NIS) actively transports two ions of sodium along with one of iodide into the cells using the favorable gradient of Na + . NIS is localized in the
C Spitzweg, P J Nelson, E Wagner, P Bartenstein, W A Weber, M Schwaiger, and J C Morris
Introduction Based on its well-characterized role in radioiodine imaging and therapy in differentiated thyroid cancer, the sodium iodide symporter (NIS) represents one of the oldest targets for molecular imaging and targeted radionuclide
Wei Li and Kenneth B Ain
, suggesting the presence of a trans -acting repressor of hNIS transcription, termed NIS-repressor ( Li et al . 2007 ). Multiple cellular and nuclear factors are reported to be important for NIS transcription, including thyrotropin (TSH)/receptor ( Riedel et
Marie-Claude Hofmann, Muthusamy Kunnimalaiyaan, Jennifer R Wang, Naifa L Busaidy, Steven I Sherman, Stephen Y Lai, Mark Zafereo, and Maria E Cabanillas
, immunotherapy can be used as an effective therapy to improve the benefits of kinase inhibitors ( Iyer et al. 2018 ). Redifferentiation therapies The uptake of iodine by thyroid follicular cells is mediated by a sodium iodide symporter (NIS) located in
Yu-Yu Liu, Xiaoli Zhang, Matthew D Ringel, and Sissy M Jhiang
Introduction The Na + /I − symporter (NIS) is a transmembrane glycoprotein that is expressed on the basolateral membrane of thyroid follicular cells. NIS-mediated iodide uptake from the circulating bloodstream into the thyroid follicular cells is